Soleno and Ultragenyx Face Securities Fraud Litigation Over Disclosure Risks

The rare disease biotechnology sector is facing a new wave of legal scrutiny as the Schall Law Firm announced separate securities fraud class action lawsuits against Soleno Therapeutics (SLNO) and Ultragenyx Pharmaceutical (RARE). These filings represent a significant development for investors in the orphan drug space, where company valuations are often precariously tied to the success of a single lead asset or the perceived transparency of regulatory interactions. The lawsuits typically allege that these companies made false or misleading statements regarding their clinical progress or failed to disclose material adverse facts that eventually led to significant stock price declines.

For Soleno Therapeutics, the litigation likely centers on the development of its lead candidate, DCCR (diazoxide choline) controlled-release tablets, intended for the treatment of Prader-Willi Syndrome (PWS). In the biotech industry, 'stock drop' litigation often follows a period of executive optimism that is abruptly corrected by a regulatory setback, such as an FDA 'refusal to file' letter or a requirement for additional, unplanned clinical trials. For a company like Soleno, which has spent years navigating the complex regulatory pathway for PWS, any perceived lack of transparency regarding FDA feedback can trigger immediate legal action from shareholder rights firms looking to recoup losses for institutional and retail investors.

“

The rare disease biotechnology sector is facing a new wave of legal scrutiny as the Schall Law Firm announced separate securities fraud class action lawsuits against Soleno Therapeutics (SLNO) and Ultragenyx Pharmaceutical (RARE).

Ultragenyx Pharmaceutical, while possessing a broader portfolio of approved rare disease therapies, faces similar pressures. As a more established player in the rare disease market, Ultragenyx is often judged on the commercial scaling of its approved products like Crysvita and Dojolvi, as well as the high-risk readouts of its gene therapy pipeline. Securities fraud allegations in this context often point to discrepancies between internal data and public disclosures regarding trial efficacy or safety signals. The Schall Law Firm's move to organize lead plaintiffs suggests a belief that the company’s disclosures did not accurately reflect the underlying risks or operational realities during the class period.